Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)2.36
  • Today's Change0.00 / 0.00%
  • Shares traded3.71m
  • 1 Year change+140.82%
  • Beta2.0697
Data delayed at least 15 minutes, as of Feb 12 2026 08:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

VIVA Biotech Holdings is an investment holding company. The Company has two segments. The Drug Discovery Services segment provides structure-based drug discovery services to biotech and pharmaceutical clients for preclinical innovative drug development. The Contract Design and Manufacturing (CDMO) and Commercialization Services segment is engaged in contract development and manufacturing services for small molecule Active Pharmaceutical Ingredients (APIs) and intermediates, as well as the trading of APIs, intermediates and finished products. The Company conducts business primarily in the United States, China, Europe and other regions.

  • Revenue in HKD (TTM)2.08bn
  • Net income in HKD195.14m
  • Incorporated2008
  • Employees2.09k
  • Location
    VIVA Biotech Holdings735 Ziping RoadZhoupu Town, Pudong New DistrictShanghai 201318ChinaCHN
  • Phone+86 2 160893288
  • Fax+86 2 158243936
  • Websitehttps://www.vivabiotech.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Essex Bio-Technology Ltd1.73bn313.18m2.51bn1.43k8.041.106.781.450.55080.55083.054.010.55962.962.841,196,360.0010.1010.2813.5613.6289.5087.7318.0518.701.82--0.113517.49-3.875.4711.610.3101-7.477.14
Jacobson Pharma Corporation Ltd1.53bn302.58m2.54bn1.79k8.361.145.631.660.15190.15190.76981.120.42992.549.06876,757.008.484.8310.296.1744.3041.2619.7314.850.902310.210.28657.097.430.069143.097.0524.0914.87
SinoMab Bioscience Ltd0.00-163.48m2.62bn61.00--8.26-----0.151-0.1510.000.22880.00----0.00-18.46-22.26-24.62-25.68-------3,832.94---7.820.6265--48.42--23.85---0.376--
AIM Vaccine Co Ltd1.43bn-304.78m3.79bn1.49k--1.01--2.65-0.2507-0.25071.183.050.1740.77241.12931,534.60-3.71-8.04-6.66-12.3171.8079.64-21.32-39.380.5882-3.700.3341--8.226.1978.69---7.20--
Beijing Luzhu Biotechnology Co Ltd0.00-153.88m4.55bn197.00--5.49-----0.7667-0.76670.004.170.00----0.00-12.48---13.69----------4.68--0.2296------32.53------
Shandong Boan Biotechnology Co Ltd857.13m36.28m4.82bn714.00121.781.9336.555.630.06360.06361.514.010.25301.341.731,054,275.001.07--1.41--71.70--4.23--1.451.810.2827--17.50--161.31------
VIVA Biotech Holdings2.08bn195.14m4.92bn2.09k32.591.119.782.370.07090.07090.68162.090.26124.244.941,008,351.003.22-1.283.81-1.5637.4434.3012.33-4.941.44--0.2283---7.8443.80244.08-8.8527.82--
Tong Ren Tang Technologies Co Ltd7.87bn488.95m5.62bn3.89k11.500.68044.540.71450.38180.38186.146.450.4820.86156.001,971,759.005.477.448.5712.0739.8242.2111.3415.102.79--0.191339.347.1810.15-11.594.55-8.303.37
Ocumension Therapeutics615.81m-282.30m5.71bn505.00--1.38--9.27-0.3768-0.37680.82235.080.15714.303.351,259,321.00-7.20-24.03-7.62-25.7142.5858.38-45.84-400.904.86--0.0223--69.38365.9529.36--213.01--
Data as of Feb 12 2026. Currency figures normalised to VIVA Biotech Holdings's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

8.38%Per cent of shares held by top holders
HolderShares% Held
Temasek Holdings Pte Ltd. (Investment Management)as of 31 Dec 2024150.00m7.04%
Dimensional Fund Advisors LPas of 05 Feb 202619.83m0.93%
SSgA Funds Management, Inc.as of 05 Feb 20264.58m0.22%
American Century Investment Management, Inc.as of 05 Feb 20262.48m0.12%
Dimensional Fund Advisors Ltd.as of 30 Nov 20251.23m0.06%
DFA Australia Ltd.as of 31 Dec 2025333.38k0.02%
Norges Bank Investment Managementas of 30 Jun 20250.000.00%
China Universal Asset Management Co., Ltd.as of 30 Jun 20250.000.00%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.